Discovery of GPR183 Agonists Based on an Antagonist Scaffold

The G protein‐coupled receptor GPR183/EBI2, which is activated by oxysterols, is a therapeutic target for inflammatory and metabolic diseases where both antagonists and agonists are of potential interest. Using the piperazine diamide core of the known GPR183 antagonist (E)‐3‐(4‐bromophenyl)‐1‐(4‐(4‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjær, Viktoria M. S., Ieremias, Loukas, Daugvilaite, Viktorija, Lückmann, Michael, Frimurer, Thomas M., Ulven, Trond, Rosenkilde, Mette M., Våbenø, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518411/
https://www.ncbi.nlm.nih.gov/pubmed/34270165
http://dx.doi.org/10.1002/cmdc.202100301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518411/
https://www.ncbi.nlm.nih.gov/pubmed/34270165
http://dx.doi.org/10.1002/cmdc.202100301

Ejemplares similares